Epidemiology of cryptococcal infection in hospitalized children

Neha S Joshi1, Brian T Fisher, Priya A Prasad

  • 1Department of General Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. joshin@email.chop.edu

Insights

Pediatric cryptococcal infections (CI) are rare but serious. Most cases occurred in immunocompromised children, not necessarily those with HIV, highlighting the need for broader diagnostic awareness.

Area of Science:

  • Pediatric Infectious Diseases
  • Mycology
  • Epidemiology

Background:

  • Cryptococcus neoformans causes opportunistic infections, primarily in adults with AIDS.
  • While recognized in HIV-negative individuals, data on pediatric cryptococcal infection (CI) remains limited.
  • This study addresses the knowledge gap regarding CI in pediatric populations.

Purpose of the Study:

  • To investigate the epidemiology and management of cryptococcal infections in pediatric patients.
  • To identify patient characteristics, underlying conditions, and treatment patterns for CI in children.
  • To determine the outcomes of pediatric CI, including mortality rates.

Main Methods:

  • Retrospective analysis of the Pediatric Health Information System database (2003-2008).
  • Inclusion of pediatric inpatients (<19 years) diagnosed with cryptococcosis or cryptococcal meningitis (CM).
  • Evaluation of underlying medical conditions, antifungal therapies, and hospital discharge disposition.

Main Results:

  • 63 pediatric CI cases identified (6.2 per million hospitalizations).
  • Most patients (63.5%) had underlying immunocompromising conditions; 21% were immunocompetent, 16% had HIV.
  • Non-CNS cryptococcosis (62%) was more frequent than CM (38%); overall in-hospital mortality was 9.5%.

Conclusions:

  • Pediatric cryptococcosis predominantly affects non-HIV-infected children, but often those with other immunocompromising conditions.
  • Treatment for CM generally followed adult guidelines, unlike non-CM cases.
  • Further research is needed to optimize management strategies for pediatric CI.
Abstract

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...